A downtrend has been apparent in Cue Biopharma, Inc. (CUE) lately. While the stock has lost 8.7% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its ...

Today is shaping up negative for Cue Biopharma, Inc. (NASDAQ:CUE) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per ...

Analyst Reni Benjamin of JMP Securities reiterated a Buy rating on Cue Biopharma (CUE – Research Report), with a price target of $15.00. Reni Benjamin has given his Buy rating due to a ...

In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Cue Biopharma (CUE – Research Report), with a price target of $2.00. Reni Benjamin has given his Buy ...

Cue Biopharma, Inc. (NASDAQ:CUE) shareholders will doubtless be very grateful to see the share price up 53% in the last quarter. But that is meagre solace in the face of the shocking decline over ...

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune ...

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...

Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to ...